Praxis outlines launch plans and FDA timelines for two drug candidates
Praxis Precision Medicines used its investor day to detail commercial strategies for relutrigine and ulixacaltamide. The FDA set PDUFA target dates of December 27, 2026 and January 29, 2027 for the two drugs respectively. Praxis announced hiring about 300 field representatives for ulixacaltamide and shared long‑term safety and efficacy data, including an 86% seizure reduction for relutrigine. The company also said it will begin new indication studies and advance two additional molecular entities in 2027.
Why it matters
The upcoming FDA decision dates create a near‑term catalyst that could affect PRAX’s valuation, and the hiring of a large sales force signals preparation for product launch. The disclosed efficacy data may support stronger pricing power if approvals are obtained.
Key facts
- 1The FDA set a PDUFA target action date of December 27, 2026 for relutrigine. investing.com
- 2The FDA set a PDUFA target action date of January 29, 2027 for ulixacaltamide. investing.com
- 3Praxis reported hiring approximately 300 field representatives for ulixacaltamide. investing.com
- 4Praxis estimated the U.S. prevalence of essential tremor at about 9 million people, with roughly 2 million seeking treatment. investing.com
- 5Data from the EMBOLD study showed an 86% reduction in seizures for relutrigine patients over 18 months. investing.com
- 6Praxis plans to start 2027 studies of ulixacaltamide in Parkinson’s disease, restless‑legs syndrome and autism spectrum disorder. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.